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Abstract 
Diabetes, a persistent endocrine disorder causing high rate of mortality, has been treated with 
adequate methods for the last hundred years after the discovery of insulin by Banting and Best 
though its clinical features were first described by the Egyptians 3000 years ago. The effective 
treatment strategies started to develop when the first oral hypoglycemic drugs, tolbutamide and 
carbutamide, came into the market. Presently, the establishment of new methods and strategies of 
combination therapy is considered to be more convenient over monotherapy. The main objective 
of this current study was to estimate a DPP-4 inhibitor named sitagliptin either alone or in a 
combination formulation with metformin. The quality of both available single and combination 
tablets of local companies with the innovator brand were also compared.  
The method followed for the determination of sitagliptin employed a RP‐HPLC procedure with 
PDA detector consisting of Luna 5µ C18column (250 mm x 4.60 mm) inserting an injection 
volume of 10µL and eluted by the mobile phase of 0.02 M potassium dihydrogen phosphate 
(pH4) and acetonitrile in a ratio of 60:40 respectively, which is pumped at a flow rate of 1.0 
mL/min. The method carried out the detection at a wavelength of 252 nm for the binary mixture 
and of 210 nm for the single sitagliptin; and had the elution time of 3.45 and 2.28 minutes for 
sitagliptin and metformin respectively. All the values for system suitability parameters were also 
feasible with this method.  
The release kinetics profile of sitagliptin was very precise and accurate and can be concluded 
that this method is suitable for any tablet containing sitagliptin in the routine analysis of quality 
control laboratory.  
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Chapter 1 
Introduction 
The term diabetes refers to a group of chronic metabolic disorders resulting from multiple 
etiologies which is characterized by chronic hyperglycemia, glycosouria, polyuria with 
interruption of carbohydrate metabolism mainly that initiates from different degree of decreased 
insulin secretion, insulin insensitivity, or both (WHO, 2015). 
A number of synchronizing system and pathways work jointly in order to maintain a healthy 
physiological state in human body. Homeostasis lies at the core of these processes. An anomaly 
of this homeostasis promotes to the initiation of an injury or a pathological state in various 
organs. Diabetes is such a type of metabolic disease which causes a number of major and some 
minor complications (Kaul et al., 2012). These complications include the risk of cardiovascular 
diseases (International Diabetes Federation Annual Report, 2013), infectious diseases, 
ophthalmic diseases (Chait and Bornfeldt, 2008; Libby, 2002; American diabetes association, 
2004; Global data on visual impairments, 2012), kidney damage (Global status report on 
noncommunicable diseases, 2011) etc. As a result the risk of mortality among the people with 
diabetes is two times higher than the non-diabetic people (Roglic et al., 2005). In addition to that, 
people with diabetes may develop other complications which include complications of 
pregnancy, fatty liver disease, periodontal disease, hearing loss and depression, etc. (National 
Diabetes Statistics Report, 2014; American diabetes association, 2004). 
1.1. Data of Increasing Number of Diabetic Patients 
Diabetes has revealed as a global epidemic with the emergence of industrialization worldwide 
and thus the burden of diabetes has become tremendous and elevating at a hazardous rate. The 
standard and the deviation in methods of data collection in different parts of the world are the 
two major reasons which make the process difficult to reach an accurate measure of prevalence. 
However, surveys give us evidence that in 1985, 30 million people had diabetes, while the 
number elevated to 150 million in 2000 that is shown in Figure 1. It is confirmed that in 2010, 
285 million adult people which was almost 6.6% of the global population were found to be 
diabetic and the estimated number of diabetic patients by 2030 will be 435 million that is 
approximately 7.8% of the adult population (Reichal and Rao, 2014; IDF Diabetes Atlas, Fourth 
edition, 2009). 
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Figure 1: Number of Diabetic Patients in Million According to the Year (Reichaland Rao, 2014; 
IDF Diabetes Atlas, Sixth edition, 2013) 
By 2025 the most affected countries will be India, China and the USA. Moreover, even today a 
large number of diabetic patients remain undiagnosed (WHO, 2015; IDF Diabetes Atlas, Sixth 
edition, 2013). 
An estimated 1.5 million deaths were directly caused by diabetes in 2012 and more than 80% of 
these deaths occur in low and middle income countries (WHO, 2015). According to WHO 
diabetes will be the seventhleading cause of death in 2030 (Mathers and Loncar, 2006). 
Consequently, diabetes has a major impact on economy of the country. It has costed the world 
economy near $376 billion in 2010 which was 11.6% of total world healthcare 
expenditure(Reichal and Rao, 2014). 
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Table 1 shows the regional overview recorded by the WHO in 2015, which slightly contradicts 
the predicted number of diabetic patients given by IDF. 
Table 1: Regional Overview with the Estimated Number of Diabetic Patients (WHO, 2015) 
Region Year 2000 (number of diabetic 
patients) 
Year 2030 (estimated number) 
South East Asia Region 46,903,000 119,541,000 
Western Pacific Region 35,771,000 71,050,100 
European Region 33,332,000 47,973,000 
American Region 33,016,000 66,812,000 
Eastern Mediterranean Region 15,188,000 42,600,000 
African Region 7,020,000 18,234,000 
World 171,000,000 366,000,000 
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1.2. Classification of Diabetes and Other Categories of Glucose Intolerance 
A classification of diabetes and other categories of glucose intolerance are shown in Table 2: 
Table 2: Classification of Diabetes and Other Categories of Glucose Intolerance (National 
diabetes data group, 1979; American diabetes association, 2004; National Diabetes Statistics 
Report, 2014) 
Class Sub class Former Terminology 
Diabetes Mellitus (DM) Insulin-dependent diabetes mellitus 
(IDDM or Type I DM) 
Juvenile diabetes 
Juvenile onset diabetes 
Juvenile onset- type diabetes Ketosis-
prone diabetes 
Brittle diabetes 
Noninsulin dependent diabetes 
mellitus (NIDDM or Type II DM) 
 Non obese NIDDM 
 Obese NIDDM 
Adult-onset diabetes 
Maturity-onset diabetes 
Maturity-onset-type diabetes 
Ketosis resistant diabetes 
Stable diabetes 
Diabetes mellitus associated with 
certain conditions and syndromes: 
 Pancreatic disease 
 Hormonal 
 Drug or chemical induced 
 Insulin receptor abnormalities 
 Certain genetic syndromes 
Secondary diabetes 
Impaired Glucose Tolerance 
(IGT) 
Non obese IGT Asymptomatic diabetes 
Chemical diabetes 
Subclinical diabetes 
Borderline diabetes 
Latent diabetes 
Obese IGT 
IGT associated with certain 
conditions and syndromes which 
may be- 
 Pancreatic disease 
 Hormonal 
 Drug or chemical induced 
insulin receptor abnormalities 
 Certain genetic syndromes 
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Table 2 (Continued) 
Gestational Diabetes    
Diabetes insipidus   
Previous Abnormality of Glucose 
Tolerance (PrevAGT) 
 Latent diabetes 
Prediabetes 
Potential Abnormality of Glucose 
Tolerance (PotAGT) 
 Prediabetes 
Potential diabetes 
 
1.3. Diabetes Mellitus: Ancient History and Discovery of Insulin  
The term diabetes mellitus has been revealed with a long history in which it was considered to be 
a disease of the kidneys. Beginning in antiquity, it was first recorded as abnormal polyuria along 
with weight loss in the Egyptian Papyrus Ebers as early as 1500 BC.In first or second century 
BC Demetrius of Apameia first introduced the term diabetes that was based from Ionic and Latin 
terms meaning that to pass through siphon. It was the Greek physician Aertaeus of Cappadocia 
(AD 30-90) who defined this term that was considered as the first accurate clinical description of 
diabetes. Diabetes was recognized as a disease of kidneys by another Greek physician Claudius 
Galen (AD 129-200). Later, Avicenna (AD 960-1037), an Arab physician, explained accurately 
the clinical features with some complications of diabetes i.e. peripheral neuropathy, gangrene 
and erectile dysfunction. Both Avicenna and Paracelsus (AD 1493-1541) emphasized on the idea 
of sweet taste of urine which was also mentioned in the Hindu medical textbooks from the fifth 
century. Indian texts referred it as illness of excessive urine, coupled with thirst and emaciation 
that affected rich people who consumed large quantities of carbohydrate. Urine was described 
here as ksaudra (sweet) or madhu (honey) meha (urine). Afterwards, another Arab physician, 
Abdel Latif el Baghdadi wrote the first extant treatise dedicated to diabetes in 1225. After the 
discovery of the circulation in 1628 by William Harvey, Thomas Willis, a physician at Guy‟s 
Hospital in London, located the origin of sweetness in blood prior to urine in 1674. Therefore, 
Willis‟ simple observation gave the disease new name as diabetes mellitus where the Latin word 
mellitus referring to honey or sweetness. On the basis of the presence of sugar like substances 
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the disease was characterized as diabetes insipidus, tasteless urine and diabetes vera, sweet urine 
by Frank after four years. The presence of excess sugar in blood was substantiated by both 
Robert Wyatt and Matthew Dobson (a Liverpool physician) more than a century later in 1774 
and 1776 respectively. Dobson believed this as a system disorder. In 1809 John Rollo, a French 
physician established the link between the consumed food and the amount of sugar in the urine 
by his pioneering work. He boosted the idea of a diet i.e. low in carbohydrates and high in fat 
and protein as a treatment which was undoubtedly a milestone until the discovery of insulin. In 
1815 a French chemist Michel Eugene Chevreul identified the sugar as glucose and then in 1857 
Claude Bernard (France) showed the glycogenic properties of the liver which was the initiating 
activity towards the discovery of the role of the pancreas as the source of insulin. Afterwards, 
diabetes had been linked to pancreas by both Richard Bright and Von Recklinhausen in 1831 and 
1864 respectively which was previously observed by Thomas Cawley in 1788. Cawley‟s initial 
simple observation was later confirmed by Oscar Minkowski and Joseph Mering in 1889 when 
they showed that pancreatectomized dogs developed diabetes. Therefore, they were the real 
explorers of the role of pancreas in pathogenesis of diabetes. Meanwhile, Paul Langerhans in 
1869 had given the explanation of unique morphologic features of the pancreatic islands. It was a 
great revolution when Edward Sharpey-Schafert recommended in 1916 that the islets of 
Langerhans produced a glucose regulating hormone which he termed insulin.  At last Frederick 
Banting and Charles Best of Toronto, Canada, isolated this hypothetical hormone in the summer 
of 1922 that was an extraordinary innovation in the history of medicine. Today the endocrine 
nature of diabetes is clearly established which interprets diabetes is not a disease of the kidneys 
rather it is a cause of kidney disease(Eknoyan and Nagy, 2005; Kirchhof et al., 2008; Ahmed, 
2002). 
1.3.1. Diabetes Mellitus 
Diabetes mellitus, a foremost factor of morbidity and premature mortality, is the disorder of 
different degrees of peripheral insulin resistance and decreased insulin secretion because of 
damaged β cell (Kaul et al., 2012).  
Some characteristic symptoms have been observed in the patients with diabetes mellitus which 
are discussed previously i.e. hyperglycemia, glycosouria, polyuria, polydypsia with polyphagia, 
fatigue, frequent episodes of thrush in penis or vagina and slow wound healing (NHS, 2014). The 
most severe forms are ketoacidosis or a non–ketotic hyperosmolar state which may develop and 
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lead to stupor, coma and, ultimately death. The effects also include long–term damage, 
dysfunction and failure of various organs. 
The pathogenic processes that are incorporated in estimation of diabetes range from the 
abnormalities in insulin action and autoimmune destruction of pancreatic β cells with impaired 
insulin secretion. As a consequence abnormal metabolism of carbohydrate, fat, and protein 
occurs. Insufficient insulin action may be the consequence of inadequate insulin secretion and/or 
decreased tissue responses to insulin. Patients may suffer from either one or both of the 
consequences but it is often unrevealed that which abnormality is the primary cause of the 
hyperglycemia, if either alone is considered (WHO, 2015; American diabetes association, 2004). 
Pancreatic β cells release insulin which stimulates the other cell of body to absorb glucose during 
high blood glucose level. Subsequently, the glucose is converted to glycogen, and to some extent 
triglycerides and protein. During decreased glucose level, α cell of pancreas secrets glucagon 
which further stimulates the liver to release glucose by the breakdown of stored glycogen. 
Insufficient insulin secretion and action result dysfunction in this homeostasis process (Kaul et 
al., 2012). 
1.3.2. Classification of Diabetes Mellitus  
The vast majority of cases of diabetes mellitus have been fallen into two broad etiopathogenic 
categories because of the dissimilarity in the mechanisms for developing the disease (Kaul et al., 
2012: National diabetes data group, 1979; American diabetes association, 2004; National 
Diabetes Statistics Report, 2014). 
 Type 1 Diabetes Mellitus 
T1DM, previously encompassed as insulin dependent diabetes or juvenile onset diabetes, is an 
autoimmune disorder which results an absolute deficiency of insulin secretion due to the 
impairment of the β cells by activated CD4+ and CD8+ T cells and macrophages attacking the 
pancreatic islets that accounts for only 5–10% of those with diabetes (Noble et al., 2011; Phillips 
et al., 2009; American diabetes association, 2004; IDF Diabetes Atlas, Sixth edition, 2013; 
Diabetes Update, 2015). The onset of this type of diabetes usually occurs in childhood as well as 
early adulthood (IDF Diabetes Atlas, Sixth edition, 2013). Since this is an autoimmune disease, 
patients suffering from this also may develop other types of autoimmune disorder like Addison‟s 
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disease, Graves‟ disease, Hashimoto‟s thyroiditis, vitiligo, celiac spure, myasthenia gravis, 
pernicious anemia and autoimmune hepatitis (American diabetes association, 2004). 
Idiopathic diabetes is another type of T1DM which does not incorporated with autoimmunity.  
Though the etiology behind it is unknown and only a small number of patients may develop it, 
this may lead to permanent insulinopenia and ketoacidosis (Kaul et al., 2012; American diabetes 
association, 2004). 
Fulminant Type 1 Diabetes Mellitus is another subtype of T1DM which has been recently 
discovered, causes extremely rapid and almost complete destruction of β cells (Hanafusa and 
Imagawa, 2007). 
Both genetic and environmental factors are known to contribute to the susceptibility to this type 
of diabetes (Kaul et al., 2012; IDF Diabetes Atlas, Sixth edition, 2013). 
o Genetic Factors 
Genetic studies have shown that the most effective genes contributing to T1DM susceptibility 
are located in the HLA (human leucocyte antigen) locus on chromosome 6 (Kaul et al., 2012; 
Noble et al., 2011; Knip et al., 2003). Locating on the cell surface the HLA proteins help the 
immune system to distinguish body‟s normal cells from foreign infectious and non-infectious 
agents. However, in T1DM, an abnormality in the HLA proteins leads to an autoimmune 
reaction against the β cells (Kaul et al., 2012) where HLA also linked to DQA and DQB genes, 
and is influenced by the DRB genes (American diabetes association, 2004). 
o Environmental Factors  
The following environmental factors may be responsible for type 1 diabetes mellitus (Knip et al., 
2003). 
1. Dietary factors 
Cow‟s milk proteins 
– Casein 
– Bovine serum albumin 
– Beta-lacto globulin 
– Bovine insulin 
Gluten and other plant proteins 
Fats 
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Nitrate and nitrite 
Coffee, tea 
Deficiency of zinc 
Vitamin D deficiency 
Frequent intake of solid foods rich in carbohydrate and protein 
2. Viral infections 
Mumps 
Rubella 
Cytomegalovirus 
Epstein-Barr virus 
Enterovirus 
Retroviruses 
Rotavirus 
3. Toxins 
Alloxan 
Streptozotocin 
N-nitroso compounds 
Bafilomycin A1 
4. Growth 
Infant growth 
Childhood growth 
5. Standard of hygiene and vaccinations 
6. Psychosocial factors 
7. Latitude and temperature 
8. Antenatal and perinatal risk factors 
 Type 2 Diabetes Mellitus 
This type of diabetes mellitus is also known as non-insulin dependent diabetes or adult-onset 
diabetes occurs due to the combination of resistance to insulin action and an inadequate 
compensatory insulin secretory response. Though the specific etiologies are unknown, this form 
of diabetes accounts for 90–95% of diabetic patients. However, it is confirmed that autoimmune 
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destruction of β-cells does not occur. Today it is increasingly observed in children and 
adolescents too. There are several important risk factors which may promote the disease i.e. 
• Obesity 
• Poor diet 
• Dyslipidemia 
• Hypertension  
• Physical inactivity 
• Advancing age 
• Ethnicity  
• High blood glucose during pregnancy affecting the unborn child 
• Family history of diabetes 
Strong genetic predisposition may be involved with it but the genetics of this form of diabetes 
are complex and not clearly defined (American diabetes association, 2004; IDF Diabetes Atlas, 
Sixth edition, 2013). 
T2DM is divided into two subgroups such as obese and non-obese. Modification in cell receptor 
develops endogenous insulin resistance which is associated with distribution of abdominal fat 
and this type of patients fall under the first group. On the other hand, insulin resistance at the 
post receptor levels causes non obese T2DM (Kaul et al., 2012; National diabetes data group, 
1979). 
1.3.3. History of Diagnosis  
Although the signs and symptoms of diabetes have been recorded since the beginnings of 
civilization, it was the nineteenth century when the diagnostic tests to define this disease have 
been started to develop. Theophilos Protospatharios (AD 630) was the first who applied heat to 
urine as a diagnostic test for diabetes. Thereafter, the first clinical test for glycosuria was 
developed in 1841 by Karl Trommer, which was a qualitative test involving the reaction of urine 
sample with a strong acid for acid hydrolysis of disaccharides into monosaccharides which 
ultimately yielded glucose. Based on this work Hermann Von Fehling developed a quantitative 
test to measure sugar content. A quantitative relationship between the degree of hyperglycemia 
and glycosuria based on Fehling‟s test was inaugurated by Frederick Pavy (1829-1911). Stanley 
Benedict, in 1907, developed a milder test for glycosuria using a copper reagent with a carbonate 
base. 
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A pioneering method was explored by Ivar Bang in 1913 to test blood glucose levels. The first 
“stick” or “strip” test (Clinitest) was introduced in 1941 by the Ames Company which was still 
based on the old methodology of Trommer‟s test involving copper sulfate reduction. Afterwards, 
the Ames Company produced the more accurate Clinistix on the basis of enzymatic reaction of 
glucose oxidase. In 1979, the diagnostic criteria of diabetes have been developed by the National 
Diabetes Data Group and the World Health Organization which incorporated measuring glucose 
tolerance using an oral glucose tolerance test (OGTT). American Diabetes Association updated 
these guidelines in 1997, and these were then revised in 2003. In order to diagnose diabetes the 
new guidelines must require meeting one of three criteria(Kirchhof et al., 2008). 
1.3.4. Diagnostic Criteria  
Sustained elevation of blood glucose defines the diabetic state clinically. It is very common to 
found the glucose concentration exceeding the normal upper limit. Today the most preferred 
method for the diagnosis of diabetes suggests measuring the blood glucose levels at different 
situation which is given below: 
1.  Random plasma glucose is equal or higher than 200 mg/dL (11.1 mmol/L) 
2. Fasting plasma glucose is equal or higher than 126 mg/dL (7.0 mmol/L) 
3. Oral glucose tolerance test (measure of plasma glucose levels 2 hr after glucose is 
given orally is greater than 200 mg/dL (11.1 mmol/L)  
According to WHO the test should be performed by administering glucose load which 
contains the equivalent of 75 g anhydrous glucose dissolved in water. 
These criteria should be confirmed by repeat testing on different day in absence of unambiguous 
hyperglycemia. For routine clinical purpose the third measure is not recommended(Mehta and 
Wolfsdorf, 2010; American diabetes association, 2004; Report of a WHO/IDF Consultation, 
2006; Kirchhof et al., 2008).  
1.4 Treatment of Diabetes Mellitus  
All types of diabetes should be treated under a close collaboration and effective management of 
diabetes requires a partnership between the diabetic patients and health professionals. The goal is 
to keep the blood glucose levels as near to normal as possible avoiding hypoglycemia, since 
there is no cure of diabetes (Kaul et al., 2012; NHS, 2014). Today the treatment strategies for 
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diabetes have been evaluated tremendously. However, the treatment regimens used has also 
significantly increased the risk of severe hypoglycemia (Mehta and Wolfsdorf, 2010)     
1.4.1. Treatment of Type 1 Diabetes Mellitus 
Avoiding its large fluctuation sustaining normal blood glucose level as near normal as possible is 
the greatest challenge in treating T1DM in order to prevent the development of microvascular 
and arterial complications. Insulin is the only treatments of T1DM which can be administered in 
injectable or inhaled forms (Press Release, 2015). Diabetes associated complications are 
prevented by using self-monitoring devices for blood glucose that also helps to adjust insulin 
dosage. It has been observed that in the early stage of β cell impairment small number of patients 
may able to secrete some insulin. Hence, insulin secretagogues and drugs are beneficial in this 
case (Kaul et al., 2012). 
1.4.2. Treatment of Type 2 Diabetes Mellitus 
First line defense against T2DM are change in lifestyle, diet, and weight control. Nevertheless, 
patients who do not respond to these, oral anti-diabetic medicines are used in the treatment which 
includes Sulfonylureas, Thiazolidinediones derivatives, Biguanides, Meglitinde analogue and 
DPP- 4 inhibitors (Kaul et al., 2012; Reichal and Rao, 2014: NHS, 2014). 
1.5 Classification of Hypoglycemic Agents 
1.5.1. Parenteral Hypoglycemic Agents 
 Drug Class: Insulin  
The hormone insulin is endogenously released from β cells of the pancreas which is found to be 
deficient in all type 1 diabetic patients as a lifelong treatment. It is also administered in type 2 
diabetic patients as either adjunct therapy to oral antidiabetic agents or as monotherapy with the 
progress of disease. Insulin molecule has been substituted and modified extensively which leads 
to multiple types of insulin. Based on their pharmacodynamic and pharmacokinetic properties 
such as onset, peak, and duration of action these are categorized as long-acting, intermediate 
acting, rapid-acting, and short-acting (Ruchalski, n.d., para. 3). 
Mechanism of Action  
The binding of insulin to α subunits of the insulin receptor results in the activation of the enzyme 
tyrosine kinase in β subunit in order to assist auto phosphorylation of it. Insulin signals the Liver 
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to convert glucose into glycogen. Insulin also triggers the glucose to adipose and skeletal muscle 
cells via glucose transporter (Kaul et al., 2012). 
The following therapeutic usage, adverse drug reactions, drug interactions and contraindications 
have been found (Ruchalski, n.d., para. 3): 
Therapeutic Usage  
o Type 1 diabetes mellitus  
o Type 2 diabetes mellitus 
o Hyperkalemia 
o Diabetic coma 
Adverse Drug Reactions  
o Hypoglycemia (anxiety, blurred vision, palpitations, shakiness, slurred speech, sweating)  
o Weight gain 
Major Drug Interactions  
Drugs affecting Insulin (Decreased Hypoglycemic Effect) 
o Acetazolamide 
o Diuretics 
o Oral contraceptives 
o Albuterol 
o Epinephrine 
o Phenothiazines 
o Asparaginase 
o Estrogens 
o Terbutaline 
o Corticosteroids 
o HIV antivirals 
o Thyroid Hormones 
o Diltiazem 
Drugs affecting Insulin (Increased Hypoglycemic Effect) 
o Alcohol 
o Fluoxetine 
o Anabolic Steroids 
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o β-Blockers 
o Sulfonamides 
o Clonidine 
Contraindications  
o Severe hypoglycemia 
o Allergy or Sensitivity to any ingredient of the product 
Members of the Drug Class  
Members of this drug class are as follows (Ruchalski, n.d., para. 3): 
o Rapid acting: Insulin glulisine, Insulin lispro, Insulin aspart 
o Intermediate acting: Insulin NPH 
o Short acting: Insulin regular 
o Long acting: Insulin glargine, Insulin detemir 
o Others: 70% NPH and 30% Regular Insulin mixture, 50% NPH and 50% Regular Insulin 
mixture, 75% Intermediate-Acting Lispro Suspension and 25% Rapid-Acting Lispro 
Solution, 70% Intermediate-Acting Aspart Suspension and 30% Rapid-Acting Aspart 
Solution  
A comparison of insulin products is shown in Table 3.  
Table 3: Comparison of Insulin Products(Ruchalski, n.d., para. 3) 
Product Onset (hours) Peak (hours) Duration (hours) 
Long-Acting 
Insulin glargine 
Insulin detemir 
 
4 
4 
 
N/A 
N/A 
 
12-24 
24 
Intermediate-Acting 
Insulin NPH 
 
2-4 
 
6-10 
 
10-16 
Short-Acting 
Insulin regular 
 
0.5-1 
 
2-3 
 
3-6 
Rapid-Acting 
Insulin glulisine 
Insulin lispro 
Insulin aspart 
 
0.25 
0.25 
0.25 
 
1-2 
1 
0.5-1.5 
 
3-5 
3-4 
3-4 
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1.5.2. Oral Hypoglycemic Agents 
 History 
Some sulphonamides with antibacterial activity could not be used clinically because of their 
convulsive side effect which brought hypoglycemia. This was firstly detected in 1930. Later, in 
1942 when a Professor of Pharmacology at Monteplier, South of France named M. J. Janbon was 
working for a cure for typhoid fever this issue was reactivated. By 1946, Loubatieres 
experimentally identified the sulphonamide group as a responsible factor for the hypoglycemic 
action. Frank and Fuchs in Berlin, Germany rediscovered sulphonamides after 10 years later 
which resulted in the development of the first two compounds (tolbutamide and carbutamide). It 
also initiated the discovery of tolazamide and chloropromide in the next decade(Ahmed, 2002). 
 Drug Class: Sulfonylurea-Insulinotropic Drugs 
The sulfonylureas are used in the treatment of patients with type 2 diabetes mellitus as adjucts to 
diet and exercise. Sulfonylureas are commonly used in combination with other oral antidiabetic 
agents sometimes in the same formulation to treat those patients who do not reach glycemic 
goals(Ruchalski, n.d., para. 4). 
Mechanism of Action  
Sulfonylureas lowers blood glucose by stimulating insulin release from β cells of the pancreatic 
islets. Their target is the ATP-sensitive potassium (KATP) channel which inhibition by 
sulfonylureas results depolarization of the β-cell membrane that in turn triggers the opening of 
voltage-gated Ca2+ channels to generate Ca2+ influx and a rise in intracellular Ca2+. As a 
consequence of which the exocytosis of insulin-containing secretory granulesare stimulated 
(Proks et al., 2002). 
The following therapeutic usage, adverse drug reactions, drug interactions and contraindications 
have been found (Ruchalski, n.d., para. 4): 
Therapeutic Usage 
o Type 2 diabetes mellitus 
Adverse Drug Reactions 
o Hypoglycemia 
o Gastro Intestinal distress 
o Dizziness 
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Major Drug Interactions 
Drug Affecting Sulfonylureas 
o Enhanced hypoglycemic effects 
Anticoagulants 
Azole antifungals  
Gemfibrozil 
o Decreased hypoglycemic effects 
β-Blockers  
Sulfonylurea Affecting Other Drugs 
o Digoxin: Increased levels 
Contraindications  
o Diabetes complicated by ketoacidosis, with or without coma 
o Diabetes complicated by pregnancy 
o Type 1 diabetes mellitus  
Members of the Drug Class 
Members of this drug class are given below (Ruchalski, n.d., para. 4): 
o First generation: Acetohexamide, Tolbutamide, Chlorpropamide, Tolazamide 
o Second generation: Glibenclamide, Gliclazide, Glimepiride, Glipizide, Glyburide  
 Drug Class: Meglitinide Analogue-Insulinotropic Drugs 
The meglitinide analogues are the class of oral antidiabetic agents which stimulate insulin 
secretion from the pancreatic β cell. Their properties assume that they have the ability to produce 
a rapid, short‐lived insulin output. Meglitinides may be used as monotherapy as an adjunct to 
diet and exercise or in combination with other oral antidiabetic agents and/or insulin to reach 
glycemic goals in patients who do not receive it on those therapies (Black et al., 2009). 
Mechanism of Action   
Meglitinides bind competitively to sulfonylurea receptors (SURs) to inhibit KATP channels and to 
stimulate insulin secretion. The insulinotropic action of meglitinide is also mediated via 
adenosine triphosphate (ATP) dependent potassium channels like the sulfonylureas. It stimulates 
insulin secretion by blocking ATP- dependent potassium channels (KATP) of the pancreatic β cell 
which results in membrane depolarization and calcium influx through voltage-gated calcium 
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channels. Finally, these activities lead to an increase in intracellular calcium and following 
exocytosis of insulin-containing granules (Mendoza et al., 2013). 
Therapeutic Usage  
o Type 2 diabetes mellitus 
Adverse Drug Reactions  
Adverse drug reactions which have been found most commonly are given below (Black et al., 
2009): 
o Weight gain 
o Diarrhea 
o Hypoglycemia  
Major Drug Interactions  
Major drugs which interact with meglitinides are as follows (DeRuiter, 2003): 
o Increased Action 
NSAIDs 
Azole antifungal (ketoconazole, miconazole) 
Antibiotics including erythromycin 
Highly protein bound drugs- cylates, sulfonamides, chloramphenicol, coumarins, 
probenecid 
o Decreased Action 
Troglitazone 
Rifampin 
Barbiturates  
Carbamazepine 
Contraindications  
The most common contraindications are as follows (Wang et al., 2015; Culy and Jarvis, 2001; 
Tornio et al., 2014): 
o Clopidogrel (a medicine used to prevent blood clot) 
o Type 1 diabetes mellitus 
o Diabetic keto acidosis 
Members of the Drug Class  
Members of this drug class are given below(Black et al., 2009): 
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o Repaglinide 
o Nateglinide  
 Drug Class: Di-Peptidyl Peptidase-4 (DPP-4) Inhibitor-Insulinotropic Drugs 
Di-Peptidyl Peptidase-4 Inhibitor is the newer member in the family of oral anti diabetic drugs 
which also stimulates insulin secretion from the pancreatic β cell. 
Mechanism of Action  
Di-Peptidyl Peptidase-4 (DPP-4) Inhibitor inhibits the breakdown of active Glucagon-like 
peptide-1 (GLP-1) to inactive GLP-1 by inhibiting the enzyme DPP-4. In response to food intake 
active GLP-1 is released from α cell of the pancreas. GLP-1 maintains blood glucose by 
enhancing the secretion of insulin from the pancreas in a glucose-dependent manner. This class 
of drugs is now being used as monotherapy as an adjunct to diet and exercise or in combination 
with other oral antidiabetic agents and/or insulin to reach glycemic goals in patients who do not 
receive it in the present therapy(Ruchalski, n.d., para. 2). 
The following thereapeutic usage, adverse drug reactions and durg interactions have been found 
(Ruchalski, n.d., para. 2): 
Therapeutic Usage  
o Type 2 diabetes mellitus 
Adverse Drug Reactions  
o Nasopharyngitis 
o Nausea 
o Vomiting 
o Diarrhea 
o Hypoglycemia 
o Weight loss 
Major Drug Interactions  
DPP-4 Inhibitors Affecting Other Drugs 
o Digoxin: Increased levels 
Members of the Drug Class  
Members of this drug class are as follows (Ruchalski, n.d., para. 2): 
o Sitagliptin (first member in this class)  
o Saxagliptin  
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 Drug Class: Biguanides- Insulin Sensitizing Agents  
The biguanides are the drugs of first choice for a newly diagnosed patient with type 2 diabetes 
which are used as an adjunct to diet and exercise. They are frequently used in the combination 
with other oral antidiabetic agents and/or insulin in patients who do not reach glycemic goals on 
the current therapies. 
Mechanism of Action  
Biguanides lower both basal and postprandial plasma glucose. Hepatic glucose productoin and 
intestinal absorption of glucose production are decreased by them. In fact peripheral glucose 
uptake and utilization are also improved(Ruchalski, n.d., para. 1). 
The following therapeutic usage, adverse drug reactions, drug interactions and contraindications 
have been found (Ruchalski, n.d., para. 1): 
Therapeutic Usage  
o Type 2 diabetes mellitus 
o Antipsychotic-induced weight gain 
Adverse Drug Reactions  
o Diarrhea 
o Vomiting 
o Dyspepsia 
o Flatulence 
o Metallic taste 
o Weight loss 
Major Drug Interactions  
Drugs Affecting Metformin 
o Alcohol  
o Iodinated cotrast media 
Contraindications  
o Renal disease 
o Heart failure requiring pharmacologic therapy 
o Accute or chronic metabolic acidosis 
o Active liver disease 
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Members of the Drug Class  
Members of this drug class are given below (Ruchalski, n.d., para. 1): 
o Metformin 
o Fenformin 
o Buformin  
 Drug Class: Thiazolidinediones- Insulin Sensitizing Agents  
Like biguanides thiazolidinediones also decrease insulin resistance by enhancing insulin-receptor 
sensitivity and are used as adjuncts to diet and exercise in patients with type2 diabetes mellitus. 
They are frequently used in combination with other oral antidiabetic agents and/or insulin in 
patients who do not reach glycemic goals on the current therapies. 
Mechanism of Action  
Insulin sensitivity is increased because of their agonistic activity to peroxisome proliferator-
activated receptor γ (PPAR γ) in turn of which insulin resistance is decreased in adipose tissue, 
skeletal muscle, and the liver(Ruchalski, n.d., para. 5). 
The following therapeutic usage, adverse drug reactions, drug interactions and contracindications 
have been found (Ruchalski, n.d., para. 5): 
Therapeutic Usage  
o Type 2 diabetes mellitus. 
Adverse Drug Reactions 
o Weight gain 
o Edema 
o Hypoglycemia (when used with insulin or other oral antidiabetic drugs) 
o Increased risk of myocardial infraction 
Major Drug Interactions  
Drug Affecting Thiazolidinediones 
o Gemfibrozil: Increased levels 
o Rifampin: Decreased levels 
Thiazolidinedione Affecting Other Drugs 
o Oral contraceptives: Decreased efficacy 
Contraindications  
o Patients with NYHA (New York Heart Association) class III and IV heart failure 
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o Concurrent insulin or nitrate use with rosiglitazone 
o Patients with hepatic dysfunction 
Members of the Drug Class  
Members of this drug class are as follows (Ruchalski, n.d., para. 5): 
o Pioglitazone 
o Rosiglitazone  
 Drug Class: α-Glucosidase Inhibitors- Insulin Sensitizing Agents 
Alpha glucosidase inhibitors (AGIs), enzyme inhibitors, are the unique class of anti-diabetic 
drugs which delay carbohydrate absorption in the gastrointestinal tract. By this way, they control 
postprandial hyperglycaemia. 
Mechanism of Action  
In order to digestion the carbohydrates need to be broken down to monosaccharides most of 
which are present as oligo or poly saccharides. Alpha amylase breaks down the starch whereas 
AGIs inhibit both alpha amylase and the other alpha-glucosidases preventing the absorption of 
starch and other carbohydrates from the brush border of the intestine. 
Therapeutic Usage  
o Type 2 diabetes mellitus 
Adverse Drug Reactions  
Undigested disaccharides which remain in the intestinal lumen may cause flatulence, diarrhea 
and abdominal pain (Kalra, 2014). 
Major drugs which may interact commonlywith AGIs and the contraindications of AGIs are 
mentioned below (Bayer HealthCare Pharmaceuticals Inc, 2011): 
Major Drug Interactions  
o Thiazides and other diuretics  
o Corticosteroids  
o Phenothiazines  
o Thyroid products  
o Estrogens 
o Oral contraceptives 
o Phenytoin 
o Nicotinic acid 
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o Sympathomimetics 
o Calcium channel-blockers 
o Isoniazid 
o Sulfonylureas  
o Insulin 
o Digoxin 
Contraindications  
o Inflammatory bowel disease 
o Disorder of digestion 
o Colonic ulceration  
o Partial intestinal obstraction 
o Cirrhosis of the liver 
Members of the Drug Class  
Members of this drug class are as follows (Kalra, 2014): 
o Acarbose 
o Voglibose  
o Miglitol  
1.6. Management of Diabetes Mellitus and Fixed Dose Combination (FDC) Therapy  
Depending upon the condition of the patient, some factors need to be taken under consideration 
for the treatment of diabetes mellitus such as degree of hyperglycemia and properties of anti-
hyperglycemic drugs. 
Management of diabetes mellitus can be classified into mainly two categories i.e.  
a) Mono-therapy medicines  
b) Combination medicines  
1.6.1. Need for Combination Therapy 
Fixed dose combination therapy (FDC) is referred to as a combination of two or more active 
ingredients in a fixed ratio of doses. According to the suggestion of International Diabetic 
Federation and American Diabetic Federation if the monotherapy fails along with lifestyle 
modification the patient should follow by combination therapy. It has been proved that 
Introduction 
23 
 
combination therapy helps to achieve and maintain the desired therapeutic targets (Reichal and 
Rao, 2014).  
The advantages of Fixed Dose Combination are as follows (Reichal and Rao, 2014)- 
o Ease of administration  
o Convenience 
o Synergistic effect 
o Complementary mechanism of action  
o Low dose with fewer side effects 
o Economical  
o Reduce the pill burden  
o Improve adherence to treatment  
o Improve tight glycemic control 
o Decrease adverse drug reactions  
o Delay the need for insulin therapy  
Various works have been done previously with the combination of diabetic drugs in bilayer 
tablets which are shown in the Table 4. 
Currently Fixed Dose Combination (FDC) of diabetic drugs is fabricated for various reasons 
which are discussed in the Table 5. 
Table 4: Combination of Diabetic Drugs in Bilayer Tablets (Reichal and Rao, 2014) 
Drugs Rationale 
1. Glibenclamide +Metformin HCl Frequency of administration is reduced 
Patient compliance is improved 
2. Pioglitazone+ Metformin HCl Patient compliance is improved  
3. Metformin HCl +Gliclazide Prolong the release up to 12hrs  
Patient compliance is improved 
4. Glimepiride + Metformin HCl Improve oral therapeutic efficacy with optimal control 
of plasma drug level 
5. Pioglitazone + Gliclazide Provide synergistic action 
6. Glipizide +Metformin HCl Provide synergistic action 
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Table 5: List of Current Fixed Dose Combinations (FDCS)(Reichal and Rao, 2014) 
Combination of Drugs  Mechanism of Action Rationale  
Metformin+ Sulfonyl 
Urea  
Metformin suppresses hepatic 
gluconeogenesis to reduce fasting 
glycemia and the peripheral glucose 
uptake. Sulfonyl ureas increase insulin 
release from β cells residual function is 
present  
Better than monotherapy 
Synergistic effect is obtained 
Metformin+ Pioglitazone  Pioglitazone increases insulin sensitivity in 
adipose tissue and inhibit β cell loss  
Synergistic effect is obtained 
Metformin+ DPP-4 
inhibitors  
Inhibits the breakdown of GLP-1 by DPP-
4 therefore increases GLP-1 levels, 
resulting in increased glucose-dependent 
insulin release and decreased level of 
circulating glucagon and hepatic glucose 
production  
Safety and tolerability (mainly 
used for early combination 
therapy)  
Metformin+ α 
Glucosidase Inhibitors  
Metformin acts on gluconeogenesis and 
Acarbose, voglibose reduce intestinal 
glucose absorption to control post pradiel 
glycemia  
Synergistic effect is obtained 
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Chapter 2 
Methodology 
The research methodology of this project has been followed based on an extensive literature 
review of the release kinetics and quality assurance of sitagliptin and metformin. 
A method should be developed with a goal to rapidly test preclinical samples, formulation 
prototypes, and commercial samples (Breaux et al., 2003).The Good Quality Control Laboratory 
Practice (GQCLP) requires test methods to assess the compliance of pharmaceutical product with 
established specification and to meet proper standard of accuracy and reliability. The validated 
method will give consistent and reliable results which are mainly concerned with source of errors 
and their estimation in the experiment. If the estimated errors are within the acceptable limit, 
then the method is said to be validated and qualified for its intended use.  
For good quality control laboratory practice, numerous methods need to be developed to 
ascertain the identity, claimed potency, strength, quality and purity of different drug substance 
and drug product. These physicochemical properties of any drug substance or others are checked 
through different test methods such as assay test or content uniformity test, dissolution test, and 
disintegration test etc. These test methods vary from one API to another. Therefore, before 
manufacturing or launching any new product to the market, different test methods specific to the 
product need to be fixed initially so that the physicochemical properties of that drug product 
could be checked whenever needed to ensure the product safety and efficacy throughout its shelf 
life including storage, distribution and use (Patil et al., 2001). 
For this purpose, pure sample of sitagliptin and metformin, available market tablets of sitagliptin 
and the combination formulation of sitagliptin and metformin were collected in the initial phase 
of the study. A system of documentation relating to the study was prepared and maintained from 
the very beginning of the study. The name of marketed products and chemicals used as reagents 
along with the apparatus used for the studies are given in the appendix 1. 
Several generic products containing sitagliptin alone and in combination with metformin have 
been registered in the world as well as in Bangladesh by several pharmaceutical companies and 
are available in the market. From a quality control point of view, to perform a comparative 
analytical evaluation between trademark and generic formulations containing sitagliptin several 
physicochemical parameters was performed to assure the quality of the generics. 
Following is a timeline showing the details of the study: 
Methodology 
26 
 
  
2.1. Literature Review  
The study commenced with an extensive review of literature. The papers related to the present 
study were selected and information was reviewed. Several HPLC methods have been reviewed 
for the determination of sitagliptin when used alone and in combination with metformin (Ramzia 
et al., 2011;Nashwahgadallah , 2014; Rezk et al., 2013; Lathareddy and Rao, 2013;  Vani et al., 
2014;Karimulla et al., 2013; Juvvigunta et al., 2013).  
Similarly, a survey of the analytical literature for HPLC, UV spectrophotometric determination 
of sitagliptin when used alone and in combination with metformin (Bhende et al., 2012; Raja and 
Rao, 2012; Jeyabalan and Nyola, 2012; Loni et al., 2012; Sankar et al., 2013), in pharmaceutical 
preparations has also been described.  
2.2. Selection of drugs 
Based on extensive literature review sitagliptin and metformin (appendix 2) were selected for the 
study. 
2.3. Sample Collection  
Five commercially available samples from different companies were collected among which 
Glipita® 50 a gift sample was received from Beximco Pharmaceuticals Ltd., Bangladesh, while 
others were purchased. Each film coated tablet contains 64.25 mg of sitagliptin Phosphate 
Literature review. 
Selection of drugs. 
Collection 
of drugs
Evaluation 
of Drugs
Determination 
of release 
kinetics of 
different 
products
Analysis of 
the results
Submission 3 Weeks 2 Weeks 1 Week 3 Weeks 4 Weeks 
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Monohydrate that is equivalent to 50 mg of sitagliptin. The reference product for the present 
study was Januvia®, the innovator brand manufactured by Merck Sharp & Dohme (MSD), Italy. 
Similarly for combination preparation, five commercially available samples from different brand 
containing 64.25 mg of sitagliptin Phosphate Monohydrate that is equivalent to 50 mg of 
sitagliptin and 500 mg of metformin Hydrochloride in each film coated tablet were collected. 
Glipita®-M 50/500, a gift sample was received from Beximco Pharmaceuticals Ltd., Bangladesh, 
while others were purchased. For the present study, Janumet® was purchased that was the 
innovator brand, Merck Sharp & Dohme (MSD), The Netherlands to use as reference product. 
Pure sample of powdered sitagliptin and metformin was received from Beximco Pharmaceuticals 
Ltd., Bangladesh as a gift having a potency of 96.4% and 99.5% respectively. All the products 
tested were stored within specified conditions and were within their expiry date. 
2.4. Tablet Evaluation 
The quantitative evaluation of a tablet‟s physicochemical parameters is essential in the design of 
the dosage form and to monitor its quality. Since chemical breakdown or interactions between 
the tablet components may occur during its manufacturing, storage and use which ultimately 
alter its physical properties as well as bioavailability, evaluation is highly important. Regarding 
the quality of tablets there are several standards which have been set in the various 
pharmacopoeias. 
The following physicochemical parameters were checked: 
1. Average weight-weight variation 
2. Friability 
3. Hardness 
4. Disintegration 
2.4.1. Average Weight-Weight Variation 
Factors which affect tablet weight are mainly tooling of the compression machine, head pressure, 
machine speed and flow properties of the powder. Common sources of weight variation are 
inconsistent powder or granulate density and particle size distribution during compression. 
Uniformity of weight is important to ensure the consistency of dosage units during compression.  
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Figure 2:Electronic Balance 
Procedure 
o Twenty tablets were taken and weighed individually using the electronic balance shown 
in Figure 2.  
o The average weight was then calculated and it was compared to the individual tablet 
weight.  
The tablet pass the USP test if no more than 2 tablets are outside the percentage limit and if no 
tablet differs by more than 2 times the percentage limit. The USP standard of percent difference 
according to average weight is shown in Table 6. 
Table 6: Pharmacopeial Standard (USP29-NF24) 
Average weight 
USP 
Percent difference 
130mg or less ±10% 
More than 130mg through 
324mg 
±7.5% 
More than 324mg ±5% 
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2.4.2. Friability  
It is another measure of a tablet‟s strength. Tablets may tend to powder and fragment during 
handling which cause lack of elegance and consumer acceptance. Friability also interferes in 
uniformity of weight as well as content uniformity. 
Friability test subjects a number of tablets to the combined effects of abrasion and shock by 
utilizing a plastic chamber that revolves at 25 rpm, dropping the tablets with each revolution. 
 
 
Figure 3: Friability Tester 
Procedure 
o Ten pre-weighed tablets were placed in the friability tester which is shown in Figure 3. 
This was operated for 100 revolutions at 25 rpm. 
o The tablets were reweighed. 
The equation by which the amount of friability can be calculated is mentioned below(Nasrin, 
2011): 
% friability = 
W0–Wf
W0
x 100% 
W0 = initial weight 
Wf = final weight 
2.4.3. Hardness 
Tablets require a certain amount of strength or hardness to withstand mechanical shocks of 
handling in manufacture, packaging and shipping as well as to withstand reasonable abuse when 
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in the hands of the consumer. The hardness of tablets is related to both disintegration and 
dissolution or, in other words, bioavailability. 
Hardness of tablet is the force required to break a tablet along its diameter by applying 
compression loading. 
Hardness variation depends on: 
o Compression force 
o Concentration and type of binding agent 
If it is too soft, it may not withstand the necessary multiple shocks occurring during handling, 
shipping, and dispensing. If the tablet initially is too hard, it may not disintegrate in the requisite 
period of time. 
 
Figure 4: Hardness Tester 
Procedure 
o A tablet was placed between two anvils, force was applied to the anvils, and the crushing 
strength that just caused the tablet to break was recorded (in kg) using the hardness tester 
shown in Figure 4. 
o In this way, hardness of 10 tablets was recorded. 
2.4.4. Disintegration Test 
This test determines whether tablets disintegrate within the prescribed time when placed in a 
liquid medium under the experimental conditions or not. 
The USP device to test disintegration uses 6 glass tubes that are 3 inch long; open at the top and 
10 mesh screens at the bottom end. The disintegration tester which was used is shown in Figure 
5. 
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Figure 5: Disintegration Tester 
Procedure 
o One tablet was placed in each tube and the basket rack was positioned in a 1L beaker of 
water which contained distilled water at 37 ± 0.5ºC.  
o The basket rack was kept such a way that during upward movement the tablet remained 
2.5 cm below the surface of liquid and during downward movement not closer than 2.5 
cm from the bottom of the beaker. 
o At a frequency of 28 cycles per minute the basket containing the tablets was moved up 
and down through a distance of 5 cm. 
o A perforated plastic disc was placed on each tablet in order to prevent floating of the 
tablets. 
The time when the tablets disintegrated and all particles passed through the 10 mesh screen was 
recorded. 
o Disintegration time for uncoated tablet: 5-30 minutes 
o Disintegration time for coated tablet: 1-2 hours 
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2.5. Determination of Release Kinetics 
In vitro dissolution measures the portion (%) of the API that has been released from the dosage 
form and has dissolved in the dissolution medium during controlled testing conditions within a 
defined period. It gives the prediction on bioavailability and thus it is one of the most important 
parameters for pharmaceutical dosage form. 
Standard dissolution method for sitagliptin alone and in combination with metformin is shown in 
Table 7 according to U.S. Food and Drug Administration. 
Table 7:Standard Dissolution Method for Sitagliptin Alone and in Combination with Metformin 
(FDA-Recommended Dissolution Methods, 2015.) 
Drug Name Dosage 
Form 
USP 
Apparatus 
Speed 
(RPMs) 
Medium Volume 
(mL) 
Sitagliptin Phosphate Tablet I (Basket) 100 Water 900  
Metformin 
HCl+Sitagliptin 
Phosphate 
Tablet II (Paddle) 75 0.025 M 
NaCl 
900 
 
USP Dissolution Apparatus  
There are two types of apparatus for dissolution. The assembly of dissolution apparatus consists 
of the following:  
A vessel made of glass or other inert, transparent material that does not interfere with the dosage 
form, a motor, a drive shaft, and a cylindrical basket in case of USP apparatus I and instead of 
basket there is paddle in USP apparatus II. The paddle is formed from a blade and a shaft which 
is used as the stirring element. Temperature inside the vessel is maintained at 37 ± 0.5 ºC during 
the test by immersing the vessel partially in a suitable water-bath of any convenient size or 
heated by a suitable device such as a heating jacket. It keeps the dissolution medium in a 
constant and smooth motion. No other part of the assembly does not cause significant motion, 
agitation or vibration beyond which because of the smoothly rotating stirring element. The vessel 
having a capacity of 1 liter is cylindrical with a hemispherical bottom. At the top its sides are 
flanged. A fitted cover can be used to retard evaporation which spares adequate openings to 
allow ready insertion of the thermometer and withdrawal of samples. The shaft is positioned in 
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order to fix its axis that is not more than 2 mm at any point from the vertical axis of the vessel. 
This ensures the rotation smooth without significant wobble that could affect the results.  
 
 
Figure 6: Dissolution Tester 
Preparation of Sodium Chloride Solution: 8.775 g of sodium chloride was weighed and 
transferred into a media bucket with 6 liter of distilled water. 
Procedure 
During the dissolution test of sitagliptin in combination with metformin the stated volume of the 
dissolution medium (± 1%) was placed in the vessel of the specified apparatus that is shown in 
Figure 6. The apparatus was then assembled and the dissolution medium was equilibrated to 37 ± 
0.5 °C. Six tablets were taken and one tablet was placed in each of the six vessels. Subsequently, 
the apparatus was operated at the specified rate. After 30 minutes from the starting time 10 mL 
of sample was collected from a point midway between the stirrer and the glass vessel. 
Since sitagliptin required USP apparatus I which is of basket type, tablets were placed here into 
the baskets instead of vessels. The other procedures were as same as the process of the 
dissolution of sitagliptin in combination with metformin. 
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2.5.1. Choice of Method 
For the estimation of sitagliptin and metformin, several methods were reviewed from different 
papers and the preferable methodology among them was eventually adopted and modified after 
undertaking several trial and error steps. 
I. According to (Bhende et al., 2012) the elution of sitagliptin and metformin was carried 
out utilizing XTerraC8column (4.6x100 mm, 3µm) with a mobile phase combination of  
phosphate buffer solution (pH 9), acetonitrile and methanol in the ratio 35:45:20 
respectively at flow rate of 0.6mL/min. The detection was carried out at a wavelength of 
260 nm.  
II. In another literature the estimation of sitagliptin and metformin was carried out on an 
XTerraC8 column (4.6x100 mm, 5µm) using a mobile phase of phosphate buffer solution 
(pH 8) in combination with acetonitrile and methanol in the ratio 45:35:20 respectively 
which was pumped at a flow rate of 1.0 mL/min with the injection volume of 20 µL at 
ambient temperature. The detection was carried out at a wavelength of 254 nm in 
accordance with (Raja and Rao, 2012).  
III. According to (Jeyabalan and Nyola, 2012) Phenomenex C18 column(4.6x250 mm, 5µm) 
in isocratic mode was used to estimate sitagliptin and metformin by a mobile phase of 
0.02 M potassium dihydrogen phosphate (pH 4.3) with acetonitrile in a ratio 55:45 
respectively. The flow rate was 1.0 mL/min with the injection volume of 20 µL and the 
final analytical determination was done using UV detector at wavelength of 252 nm.  
IV. A literature from (Loni et al., 2012) Hi-Q Sil C18 column (4.6x250 mm, 5µm) was used 
with a mobile phase containing phosphate buffer solution (pH 4), acetonitrile and 
methanol in a ratio 50:20:30 respectively and a flow rate of 1.2 mL/min with 20 µL 
injection volume. The analytes were detected through UV detector at wavelength of 258 
nm.  
V. According to (Sankar et al., 2013) the determination of sitagliptin and metformin was 
carried out on a Phenomenex Luna C18 column (4.6x250 mm, 5µm) in isocratic mode. 
An injection volume of 20µL was injected and eluted with mobile phase 0.02 M 
potassium dihydrogen phosphate (pH 4) and acetonitrile in a ratio 60:40 respectively 
pumped at a flow rate of 1.0 mL/min. The detection was carried out at a wavelength of 
252 nm.  
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VI. Finally, one method was done as a trial and error method using Luna 5µ C18column (250 
mm x 4.60 mm) in isocratic mode through a mobile phase consisting of dipotassium 
hydrogen phosphate (pH 7.2) and acetonitrile in a ratio 70:30 respectively. An injection 
volume of 10µL was injected with a flow rate of 1.0 mL/min. The analytes were detected 
through UV detector at wavelength of 210 nm. 
This method was adopted from a company (primary source). 
All the tests mentioned above were carried out and method according to Sankar et al., 2013 was 
found to give the most optimum response with least interference.  
2.5.2. Choice of Mobile Phase 
At the initial point of the study, for the selection of mobile phase, the various compositions of 
mobile phase verification were carried out for the gradient elution of sitagliptin and metformin 
are mentioned as follows: 
Mobile Phase 1 : pH 4 0.02 M Potassium dihydrogen phosphate: acetonitrile (60:40) 
Mobile Phase 2 : pH 4 Phosphate buffer solution: acetonitrile: methanol (50:20:30) 
Mobile Phase 3 : pH 4.3 0.02 M Potassium dihydrogen phosphate: acetonitrile (55:45) 
Mobile Phase 4 : pH 7.2 Dipotassium hydrogen phosphate: acetonitrile (70:30) 
Mobile Phase 5 : pH 8 Phosphate buffer solution: acetonitrile: methanol (45:35:20) 
Mobile Phase 6 : pH 9 Phosphate buffer solution: acetonitrile: methanol (35:45:20) 
Initially mobile phase containing dipotassium hydrogen phosphate (pH 7.2) and acetonitrile 
(70:30) had been selected but it had a run time of 20 minutes which was undoubtedly very much 
time consuming as well as expensive. Similarly we had observed the trial at higher pH using 
Mobile Phase 5 and Mobile Phase 6. After that we came to a very interesting conclusion that was 
pH had a major effect on the elution of these analytes specially sitagliptin. This was one of the 
reasons why these particular mobile phases with high pH system were discarded. 
On the other hand among the mobile phase of lower pH, Mobile Phase 1 was chosen because of 
its least interference on the system and sharp as well as completely resolved peak. 
The chromatographic condition is given in Table 8. 
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Table 8: Chromatographic Condition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromatographic Mode Chromatographic condition 
Mobile Phase 0.02 M Potassium dihydrogen phosphate pH4: 
acetonitrile (60:40% v/v) 
Stationary phase 
Luna 5µ C18column (250 mm x 4.60 mm) 
Flow Rate 1.0 mL/min 
Injection Volume 10µL 
Diluent Water 
Temperature 25ºC 
Elution Isocratic 
Detection for sitagliptin alone UV, absorbance at 252 nm 
Detection for sitagliptin in combination with 
metformin 
UV, absorbance at 210 nm 
Run Time 4 minutes 
Retention time Metformin: Approximately 2.4 minutes 
Sitagliptin:  Approximately 3.4 minutes 
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Figure 7: HPLC Machine 
2.5.3. Instrumentation (Mubtasim et al., 2015) 
The HPLC system was composed of following parts (Figure 7): 
o A high pressure binary gradient pump which is Shimadzu LC-20AT 
o Auto sampler named SIL-20AHT 
o CTO-10ASvp column temperature oven 
o PDA detector named SPD-M20A 
o CBM-20 Alite system controller 
o Lab solution LC workstation multi PDA software 
2.5.4. Preparation 
Buffer Solution: Accurately 2.72 g of potassium dihydrogen phosphate was weighed and 
transferred into a volumetric flask containing distilled water. pH 4 was adjusted by adding 
diluted orthophosphoric acid using a pH meter shown in Figure 8. Final volume was adjusted up 
to 1 liter by the addition of distilled water.  
Mobile Phase: A mixture of buffer solution and acetonitrile (HPLC Grade) was prepared at a 
ratio of 60:40 and it was then filtered through 0.22 µm Restek membrane filter. 
Standard Solution for Sitagliptin in Combination with Metformin: 12.5 mg of sitagliptin and 
125 mg of metformin were weighed and then transferred into 250 ml volumetric flask. The 
Figure 8: pH Meter 
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mixture was dissolved with the dissolution media i.e. 0.025 M NaCl solution and the final 
volume was adjusted to 250 ml with the same solvent. 
Standard Solution for Sitagliptin Alone: 12.5 mg of sitagliptin was weighed which was then 
transferred into 250 ml volumetric flask. It was dissolved with the dissolution media i.e. distilled 
water and the final volume was adjusted to 250 ml using the same solvent. 
Sample Solution: The 10 mL of sample that was withdrawn from a point midway between the 
stirrer and the glass vessel after 30 minutes from the starting time of dissolution was filtered 
through 0.22 µm Restek syringe filter.  
Procedure: 
The vials containing standard and sample were placed into the tray of auto sampler of Shimadzu 
HPLC and they were injected under the following chromatographic conditions. The 
concentrations of standard and sample are as below: 
o Concentration of metformin in Standard and Sample: 0.5mg/mL 
o Concentration of sitagliptin in Standard and Sample: 0.05 mg/mL 
Chromatographic Conditions 
Apparatus  : Shimadzu HPLC-prominence integrated with PDA detector 
Column  : Luna 5µ C18column (250 mm x 4.60 mm) 
Mobile Phase  : 0.02 M Potassium dihydrogen phosphate pH-4: acetonitrile (60:40% v/v)  
Flow Rate  : 1.0 mL/min 
Diluent  : Water 
Injection Volume : 10µL 
Temperature  : 25ºC 
Detection : UV, absorbance at 252 nm for sitagliptin alone and at 210 nm for 
sitagliptin in combination with metformin 
Run Time  : 4 Minutes 
Elution  : Isocratic 
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Chapter 3  
Data Analysis 
All the data obtained were then carefully analyzed and the results interpreted as described in the 
following sub-sections. 
3.1. Data Analysis of Combination Preparation of Sitagliptin and Metformin 
3.1.1. Average Weight-Weight Variation 
Result of average weight-weight variation test for the combination formulation containing 
sitagliptin and metformin is shown in Table 9 and Figure 9.  
Table 9: Average Weight-Weight Variation Test Result of Marketed Tablets Containing 
Sitagliptin in Combination with Metformin 
Brand  IB LC1 LC2 LC3 LC4 
Weight (mg) 
Tablet no. 1 
697.00 700.00 695.00 670.00 656.00 
Tablet no. 2 697.00 703.00 729.00 661.00 653.00 
Tablet no. 3 708.00 701.00 726.00 668.00 651.00 
Tablet no. 4 698.00 704.00 720.00 662.00 655.00 
Tablet no. 5 688.00 706.00 705.00 662.00 642.00 
Tablet no. 6 693.00 707.00 712.00 660.00 646.00 
Tablet no. 7 700.00 694.00 716.00 667.00 647.00 
Tablet no. 8 701.00 710.00 700.00 660.00 650.00 
Tablet no. 9 694.00 708.00 693.00 649.00 675.00 
Tablet no. 10 698.00 703.00 710.00 655.00 659.00 
Tablet no. 11  708.00 709.00 721.00 640.00 654.00 
Tablet no. 12 686.00 700.00 705.00 670.00 651.00 
Tablet no. 13 700.00 701.00 700.00 665.00 667.00 
Tablet no. 14 698.00 690.00 702.00 660.00 640.00 
Tablet no. 15 702.00 695.00 680.00 659.00 650.00 
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Tablet no. 16 697.00 701.00 700.00 660.00 651.00 
Tablet no. 17 695.00 702.00 687.00 641.00 652.00 
Tablet no. 18 700.00 702.00 658.00 650.00 635.00 
Tablet no. 19 691.00 699.00 705.00 669.00 655.00 
Tablet no. 20 695.00 698.00 710.00 660.00 661.00 
Average (mg) 697.00 701.65 703.70 659.40 652.50 
Standard 
Deviation 
5.53 5.06 16.49 8.67 8.95 
RSD% 0.79 0.72 2.34 1.31 1.37 
 
 
Figure 9: Average Weight-Weight Variation Test Result of Marketed Tablets Containing 
Sitagliptin in Combination with Metformin 
Interpretation 
From the result of experiment for average weight-weight variation test it has been observed that 
the relative standard deviations are less than 5% for all the marketed products which is within 
acceptable range according to USP29-NF24. However, the RSD of LC2 is very much higher than 
the innovator brand which may be due to the lack of uniformity in granule size during 
compression, poor flow ability of granules, improper distribution of particles, improper use of 
lubricant and glidant, etc.      
Table 9 (Continued) 
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3.1.2. Friability 
Result of friability test for the combination formulation containing sitagliptin and metformin is 
shown in Table 10.  
Table 10: Friability Test Result of Marketed Tablets Containing Sitagliptin in Combination with 
Metformin 
Brand  Initial Weight, W0 (mg) Final Weight, Wf (mg) 𝐖𝟎–𝐖𝐟
𝐖𝟎
𝐱𝟏𝟎𝟎% 
IB 6972.00 6972.00 0.00 
LC1 7036.00 7036.00 0.00 
LC2 7109.00 7109.00 0.00 
LC3 6614.00 6602.00 0.18 
LC4 6534.00 6534.00 0.00 
Interpretation 
From the result of experiment for friability test it has been observed that for most of the 
marketed products the amount of friability found is 0%. Only one has the friability of 0.18% 
which is very negligible.  
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3.1.3. Hardness 
Result of hardness test for the combination formulation containing sitagliptin and metformin is 
shown in Table 11 and Figure 10. 
Table 11:Hardness Test Result of Combination Preparation of Marketed Tablets Containing 
Sitagliptin in Combination with Metformin 
Brand  IB LC1 LC2 LC3 LC4 
Hardness (kg) 
Tablet no. 1 
20.58 17.91 13.71 19.25 13.38 
Tablet no. 2 18.11 15.20 17.63 16.46 13.06 
Tablet no. 3 18.52 15.77 21.31 20.34 12.82 
Tablet no. 4 20.14 19.33 20.01 18.32 12.09 
Tablet no. 5 22.28 19.81 17.55 17.59 12.21 
Tablet no. 6 21.39 18.07 19.17 19.00 14.64 
Tablet no. 7 21.87 18.36 13.10 17.31 11.36 
Tablet no. 8 21.03 19.53 16.01 18.36 12.21 
Tablet no. 9 21.51 19.61 20.01 20.42 12.01 
Tablet no. 10 21.45 19.00 21.07 22.00 14.84 
Average (kg) 20.68 18.26 17.96 18.91 12.86 
 
 
Figure 10: Hardness Test Result of Combination Preparation of Marketed Tablets Containing 
Sitagliptin in Combination with Metformin 
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Interpretation 
Analysis of the result received from the above data, it can be said that most of the tablets were 
not so hard or too soft compared to innovator brand. Therefore, these tablets are considered as 
acceptable except LC4from this evaluation test. The possible reason behind this may be the lack 
of proper binding agent during formulation. 
3.1.4. Disintegration Test 
Result of disintegration test for the combination formulation containing sitagliptin and 
metformin is shown in Table 12 and Figure 11. 
Table 12: Disintegration Test Result of Marketed Tablets Containing Sitagliptin in Combination 
with Metformin 
Brand  IB LC1 LC2 LC3 LC4 
Time (minute) 
Tablet no. 1 
5.06 6.21 7.12 5.34 4.12 
Tablet no. 2 5.08 6.25 7.18 5.43 4.2 
Tablet no. 3 5.10 6.33 7.22 5.52 4.38 
Tablet no. 4 5.18 6.56 7.36 5.58 4.5 
Tablet no. 5 5.22 7.05 7.51 5.58 4.59 
Tablet no. 6 5.25 7.15 7.59 6.18 5.08 
Average (minute) 5.15 6.59 7.33 5.61 4.48 
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Figure 11: Disintegration Test Result of Marketed Tablets Containing Sitagliptin in Combination 
with Metformin 
Interpretation 
From the above result it has been seen that the total disintegration time for all the marketed 
products were not too much. So the onset time of these film coated tablets are acceptable. 
However, there was a difference between some of the brands which may be due to the binding 
agent used, type and amount of disintegrant, method of manufacture, etc. 
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3.2. Data Analysis of Single Sitagliptin Preparation 
3.2.1. Average Weight-Weight Variation 
Result of average weight-weight variation test for the formulation containing sitagliptin is shown 
in Table 13 and Figure 12.  
Table 13: Average Weight-Weight Variation Test Result of Marketed Tablets Containing 
Sitagliptin 
Brand  IB LC1 LC2 LC3 LC4 
Weight (mg) 
Tablet no. 1 
205.00 201.00 190.00 204.00 156.00 
Tablet no. 2 210.00 205.00 189.00 205.00 159.00 
Tablet no. 3 209.00 208.00 191.00 204.00 160.00 
Tablet no. 4 206.00 204.00 186.00 204.00 157.00 
Tablet no. 5 211.00 203.00 187.00 207.00 159.00 
Tablet no. 6 211.00 206.00 191.00 205.00 162.00 
Tablet no. 7 207.00 204.00 192.00 208.00 161.00 
Tablet no. 8 209.00 203.00 192.00 208.00 160.00 
Tablet no. 9 205.00 200.00 192.00 213.00 164.00 
Tablet no. 10 209.00 204.00 187.00 205.00 161.00 
Tablet no. 11 206.00 202.00 191.00 205.00 161.00 
Tablet no. 12 209.00 207.00 188.00 207.00 163.00 
Tablet no. 13 211.00 211.00 186.00 208.00 157.00 
Tablet no. 14 210.00 209.00 189.00 205.00 160.00 
Tablet no. 15 209.00 204.00 193.00 206.00 158.00 
Tablet no. 16 206.00 205.00 186.00 209.00 159.00 
Tablet no. 17 207.00 208.00 192.00 203.00 160.00 
Tablet no. 18 209.00 209.00 195.00 209.00 155.00 
Tablet no. 19 207.00 207.00 188.00 205.00 158.00 
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Table 13 (Continued) 
Tablet no. 20 208.00 204.00 189.00 205.00 157.00 
Average (mg) 208.20 205.20 189.70 206.25 159.35 
Standard 
Deviation 
1.96 2.88 2.59 2.38 2.32 
RSD% 0.94 1.40 1.36 1.15 1.45 
 
 
Figure 12: Average Weight-Weight Variation Test Result of Marketed Tablets Containing 
Sitagliptin 
Interpretation 
From the result of experiment for average weight-weight variation test it has been observed that 
the relative standard deviations are less than 7.5% for all the marketed products which is within 
the limit according to USP29-NF24.However, the RSD of LC1, LC2 and LC4 is higher than the 
innovator brand which may be due to the lack of uniformity in granule size during compression, 
poor flow ability of granules, improper distribution of particles, improper use of lubricant and 
glidant, etc.      
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3.2.2. Friability 
Result of friability test for the formulation containing sitagliptin is shown in Table 14. 
Table 14:Friability Test Result of Marketed Tablets Containing Sitagliptin 
Brand Name Initial Weight, Wo 
(mg) 
Final Weight, 
Wf (mg) 
𝐖𝟎 –𝐖𝐟
𝐖𝟎
𝐱 𝟏𝟎𝟎% 
IB 2093 2093 0 
LC1 2043 2043 0 
LC2 1887 1887 0 
LC3 2059 2059 0 
LC4 1598 1598 0 
Interpretation 
From the result of experiment for friability test it has been observed that for all of the marketed 
products the amount of friability found is 0%.  
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3.2.3. Hardness 
Result of hardness test for the formulation containing sitagliptin is shown in Table 15 and Figure 
13. 
Table 15:Hardness Test Result of Combination Preparation of Marketed Tablets Containing 
Sitagliptin 
Brand  IB LC1 LC2 LC3 LC4 
Hardness (kg) 
Tablet no. 1 
9.02 9.26 6.02 8.45 3.19 
Tablet no. 2 9.58 7.56 6.39 9.54 1.82 
Tablet no. 3 9.58 7.16 7.16 7.80 2.91 
Tablet no. 4 9.54 6.31 6.31 9.06 2.35 
Tablet no. 5 9.42 6.87 5.54 8.45 2.59 
Tablet no. 6 9.78 6.06 5.82 8.45 2.79 
Tablet no. 7 9.10 5.74 6.39 8.65 3.76 
Tablet no. 8 8.85 6.95 5.42 9.06 2.91 
Tablet no. 9 8.73 6.43 5.94 8.32 2.65 
Tablet no. 10 9.45 5.74 6.06 8.62 2.42 
Average (kg) 9.31 6.81 6.11 8.64 2.74 
 
 
Figure 13: Hardness Test Result of Marketed Tablets Containing Sitagliptin  
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Interpretation 
From this result we can conclude that one of the generics had a very low hardness compared to 
innovator brand while others passed the test. It may be due to the lack of proper binding agent 
during formulation. 
3.2.4. Disintegration Test 
Result of disintegration test for the formulation containing sitagliptin is shown in Table 16 and 
Figure 14. 
Table 16: Disintegration Test Result of Marketed Tablets Containing Sitagliptin 
Brand  IB LC1 LC2 LC3 LC4 
Time (minute) 
Tablet no. 1 
0.30 0.08 3.20 0.15 0.52 
Tablet no. 2 0.31 0.09 3.25 0.17 0.55 
Tablet no. 3 0.31 0.10 3.36 0.18 1.00 
Tablet no. 4 0.33 0.13 3.45 0.20 1.02 
Tablet no. 5 0.34 0.15 4.10 0.22 1.05 
Tablet no. 6 0.35 0.16 4.21 0.25 1.09 
Average (minute) 0.32 0.12 3.59 0.19 0.87 
 
 
Figure 14: Disintegration Test Result of Marketed Tablets Containing Sitagliptin 
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Interpretation 
From the above result it has been seen that the total disintegration time for all the marketed 
products were not too much. In fact very fast disintegration is found except generic. 
Therefore,compared to the innovator brand this generic did not pass the test while others are 
acceptable. It is may be due to the binding agent used, type and amount of disintegrant, method 
of manufacture, etc. 
3.3. Estimation of Release Kinetics 
3.3.1. System Suitability Test 
After sufficient time had passed for HPLC system to achieve a stable baseline, system suitability 
was determined by injecting standard solution to the HPLC system. This suitability test was 
applied to the chromatograms of taken under optimum conditions to check various parameters 
such as column efficiency (theoretical plates), peak area, tailing factor, retention time, and 
resolution (Celebier et al., 2010). 
Freshly prepared standard stock solution of sitagliptin alone and sitagliptin in combination with 
metformin were injected into the chromatographic system under the optimized chromatographic 
conditions (Sankar et al., 2013). The test is considered valid if the following considerations are 
met: 
 The relative standard deviation for the peak area response for six replicate injections of 
standard preparation is not more than 2% (Qiu et al., 2009) 
 Tailing factor for the peak should not be more than 2%. 
 Theoretical plate for the peak obtained in the chromatogram of standard solution is not less 
than 3000. 
After the test we obtained the following chromatograms shown in Figure 15 and 16, and the 
results are interpreted in Table 17 and 18. 
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Figure 15: Chromatogram of Standard Sitagliptin and Metformin 
 
Table 17: System Suitability Parameters of Standard Sitagliptin and Metformin 
No.  Tailing factor Theoretical plate Peak area Retention time 
1 1.290 3072.000 3934890.000 2.292 
2 1.292 3141.000 3938814.000 2.286 
3 1.293 3051.000 3937037.000 2.290 
4. 1.286 3120.000 3961279.000 2.284 
5. 1.289 3153.000 3963069.000 2.295 
6. 1.290 3102.000 3936220.000 2.286 
Average 1.290 3106.500 3945218.167 2.288 
STD 0.002 39.561 13207.463 0.004 
RSD (%) 0.189 0.012 0.334 0.184 
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Figure 16: Chromatogram of Standard of Sitagliptin 
 
Table 18:System Suitability Parameters of Standard Sitagliptin 
No. Tailing factor Theoretical plate Peak area Retention time 
1 1.292 8317.000 579943.000 3.420 
2 1.306 8038.000 553714.000 3.424 
3 1.291 8398.000 549199.000 3.417 
4. 1.297 7570.000 577619.000 3.467 
5. 1.294 7660.000 556273.000 3.459 
6. 1.298 7560.000 565321.000 3.455 
Average 1.296 7924.000 563678.166 3.440 
STD 0.005 379.375 12848.018 0.022 
RSD (%) 0.421 4.787 2.279 0.649 
Interpretation 
It is observed from the above tabulated data that the method complies with the system suitability 
parameters. Here, the relative standard deviation for the peak area response for six replicate 
injections of standard preparation of sitagliptin is approximately 2%. Hence, it can be concluded 
that the system suitability parameters meets the requirement of this method. 
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3.3.2. Estimation of Release Kinetics of Sitagliptin in Combination with Metformin 
After injecting the sample containing sitagliptin in combination with metformin into the 
chromatographic system, following chromatograph was obtained (Figure 17) and the results are 
interpreted in Table 19 and Figure 18. 
 
Figure 17: Chromatogram of Sample Sitagliptin and Metformin 
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Table 19: Dissolution Test Result of Marketed Tablets Containing Sitagliptin in Combination 
with Metformin 
Brand  IB LC1 LC2 LC3 LC4 
A B A B A B A B A B 
Tablet no. 
1 
97.44 119.79 98.08 120.05 100.73 125.18 99.17 127.10 98.26 124.34 
Tablet no. 
2 
97.43 119.68 98.02 119.56 100.33 123.63 99.16 126.28 98.18 123.23 
Tablet no. 
3 
96.70 119.52 97.83 119.05 97.90 118.84 99.10 125.74 97.11 123.11 
Tablet no. 
4 
96.65 119.35 97.75 118.95 97.83 117.95 95.72 124.26 97.09 123.06 
Tablet no. 
5 
94.94 115.03 96.98 118.55 97.82 117.29 95.61 120.16 97.01 122.62 
Tablet no. 
6 
94.78 114.69 96.95 118.40 97.45 117.16 95.44 120.01 96.99 122.32 
Average 96.32 118.01 97.60 119.09 98.67 120.01 97.36 123.92 97.44 123.11 
A= Dissolution% of Metformin, B= Dissolution% of Sitagliptin 
 
 Figure 18: Dissolution Test Result of Marketed Tablets Containing Sitagliptin in 
Combination with Metformin 
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Interpretation 
In the above result all the generics compared to the innovator brand have shown a satisfactory 
amount of release of sitagliptin in binary mixture with metformin. 
3.3.3. Estimation of Release Kinetics of Sitagliptin 
After injecting the sample containing sitagliptin into the chromatographic system, following 
chromatograph was obtained (Figure 19) and the results are interpreted in Table 20 and Figure 
20. 
 
Figure 19: Chromatogram of Sample Sitagliptin 
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Table 20: Dissolution Test Result of Marketed Tablets Containing Sitagliptin 
Brand  IB LC1 LC2 LC3 LC4 
Dissolution% 
Tablet no. 1 
114.37 97.45 102.95 115.94 119.96 
Tablet no. 2 114.09 96.91 102.73 115.53 119.64 
Tablet no. 3 113.49 94.97 101.18 113.6 118.69 
Tablet no. 4 113.25 94.47 101.08 113.23 118.63 
Tablet no. 5 111.24 93.74 100.39 110.70 118.25 
Tablet no. 6 110.22 93.42 100.34 109.86 117.98 
Average 112.77 95.16 101.44 113.14 118.85 
 
 
Figure 20: Dissolution Test Result of Marketed Tablets Containing Sitagliptin 
Interpretation 
In the above result most generics compared to the innovator brand have shown a satisfactory 
amount of release of sitagliptin except one which may be due to putting inappropriate amount of 
active ingredient during formulation. 
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Chapter 4 
Discussion 
The present work done on this combination preparation of sitagliptin and metformin, and 
sitagliptin alone in pharmaceutical tablet formulation encompasses a comparison of the local 
generic products with the innovator brand. Following the Good Quality Control Laboratory 
Practice (GQCLP), a comparative analytical evaluation between these formulations containing 
sitagliptin of several physicochemical parameters was performed to assure the quality of the 
generics.In average, weight variation test for both the combination preparation and single 
sitagliptin preparation though the generics passed the test according to USP, although some of 
them were found to be deviated from the innovator brand. Similarly, in both hardness tests and in 
vitro disintegration tests there were anomaly in the tablets of some generics. Therefore, 
compared to the innovator brand those particular generics did not pass those specific tests. These 
deviations may be the consequence of lack of uniformity in granule size, poor flow ability, 
inappropriate distribution of particles, improper use of binder, lubricant, disintegrant, etc. 
However, some of the generics were found to meet the criteria of these physicochemical 
parameters. In fact, better resultshave been observed in some cases which may be due to the 
development of new formulation by local companies. On the whole, all the generics have shown 
an acceptable result in friability test. 
Most of the generics met the criteria of release kinetics compared to innovator brand for both 
combination preparation and single sitagliptin preparation. Only one generic has found with 
lower amount of release in sitagliptin single preparation compared to innovator brand. Here, the 
one important factor that was noticed was the release of sitagliptin in both single and 
combination preparation to be greater than 100%. Companies adding an excess amount of active 
ingredient in order to get better patient compliancemay bea possible reason of this result.  
During the study of release kinetics, several analytical methods were reviewed and several trials 
were undertaken on the chosen methods. The chosen optimized method was found to comprise 
of a simple, precise and accurate method by reverse phase high performance liquid 
chromatography for the estimation of sitagliptin. The method employed a RP‐HPLC procedure 
with PDA detector consisting of Luna 5µ C18column (250 mm x 4.60 mm) inserting an injection 
volume of 10µL and eluted by the mobile phase of 0.02 M potassium dihydrogen phosphate 
(pH4) and acetonitrile in a ratio of 60:40 respectively, which is pumped at a flow rate of 1.0 
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mL/min, carried out the detection at a wavelength of 252 nm for the binary mixture and of 210 
nm for the single sitagliptin. The peaks of both sitagliptin and metformin were found to be 
precise and well separated at approximate 3.45 and 2.28 minutes respectively. The chosen RP-
HPLC method was found rapid, accurate, precise, specific, robust, economical and less time 
consuming. The values for system suitability parameter also showed feasibility of this selected 
method for routine pharmaceutical application. The changes in proportion of solvents were 
studied also in the initial phase of the study. Hence, the selected method was itself sophisticated 
enough to estimate simultaneously sitagliptin alone and in binary mixture with metformin in bulk 
and tablet dosage form.  
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Chapter 5 
Concluding Remarks 
Presently, it has become an urge to develop new strategies in the treatment of diabetes mellitus. 
Since diabetes is a lifelong condition, it cannot be cured. It can only be managed or controlled 
where the most effective treatment is based on the collaboration between patients and health 
professional. However, the life style of a patient is not persistent. So, with the modification of 
life style, the patient should be treated through newer strategies which can be combination 
therapy. This strategy has been already proved as convenient, economical with fewer side 
effects. This combination therapy also has synergistic effect with complementary mechanism of 
action since it contains more than one active pharmaceutical ingredient. Reducing the pill burden 
improves patient compliance and delays the need for insulin therapy. In our study, we estimated 
sitagliptin, a DPP-4 inhibitor, either alone or a binary mixture with metformin that is a biguanide 
derivative by using RP-HPLC method. Here, we collected almost all the available products from 
local market and have shown a comparison of the quality of marketed product between the local 
companies with the innovator brand. Though most of the local companies passed the test, some 
failed to meet the criteria of innovator brand. Therefore, physicians prescribing this drug must be 
aware of this. On the other hand, the method which we utilized for the assessment of sitagliptin 
was highly sophisticated giving an optimum, precise and accurate results rapidly. Therefore, it 
can be concluded that the present RP-HPLC method is appropriate and can be used for routine 
analysis in the quality control laboratories for any tablet dosage form containing sitagliptin. 
Furthermore, this method can be applied by changing various parameters or formulation of the 
dosage forms in future so that it can be determined that whether there is any interference of 
excipients on the rapidity and accuracy of the method. This will definitely be an actual 
robustness of this method. 
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Appendix 1 
Table 21: Name of the Marketed Product 
Sitagliptin in combination with Metformin 
Brand Name Amount of 
API 
Manufacturer Batch no. Manufacturing 
Date 
Expiry Date 
Janumet® 
(Innovator 
Brand) 
Sitagliptin 
50 mg, 
Metformin 
500 mg 
Merck Sharp & 
Dohme, The 
Netherlands  
L002021 September, 2014 September, 
2016 
Glipita®-M 
50/500 
Sitagliptin 
50 mg, 
Metformin 
500 mg 
Beximco 
Pharmaceuticals 
Ltd., Bangladesh 
SYD057 April, 2015 April, 2017 
Sitomet® 
50/500 
Sitagliptin 
50 mg, 
Metformin 
500 mg 
ACI Ltd., 
Bangladesh 
EO56 February, 2015 February, 
2017 
Janmet 500 
Sitagliptin 
50 mg, 
Metformin 
500 mg 
The ACME 
Laboratories Ltd., 
Bangladesh 
T2385004 February, 2015 February, 
2017 
Sliptin-M 500 
Sitagliptin 
50 mg, 
Metformin 
500 mg 
Drug International 
Ltd., Bangladesh 
 
0215 January, 2015 January, 2017 
Sitagliptin Alone 
Brand Name Amount of 
API 
Manufacturer Batch no. Manufacturing 
Date 
Expiry Date 
Januvia® 
(Innovator 
Brand) 
Sitagliptin 
50 mg 
Merck Sharp & 
Dohme, Italy 
15FC002A July, 2014 June, 2016 
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Glipita® 50 Sitagliptin 
50 mg 
Beximco 
Pharmaceuticals 
Ltd., Bangladesh 
SYC060 March, 2015 March, 2017 
Sitap® 50 Sitagliptin 
50 mg 
ACI Ltd., 
Bangladesh 
EO75 February, 2015 February, 
2017 
Janvia 50 Sitagliptin 
50 mg 
The ACME 
Laboratories Ltd., 
Bangladesh 
T2484055 December, 2014 December, 
2016 
Sliptin 50 Sitagliptin 
50 mg 
Drug International 
Ltd., Bangladesh 
0515 May, 2015 May, 2017 
 
Other marketed products are reported in Bangladesh National Formulary (BDNF) but were 
unavailable in the market at the time of study. 
Table 22: List of Chemicals Used 
Name Manufacturer 
Acetonitrile Active Fine Chemicals Ltd, Bangladesh 
Methanol Active Fine Chemicals Ltd, Bangladesh 
Potassium Dihydrogen Phosphate Scarlab, Spain 
Dipotassium Hydrogen Phosphate Merck Specialties Private Ltd., India 
Sodium Chloride Cryst. Pure Merck Specialties Private Ltd., India 
Sodium Hydroxide Pellets Merck Specialties Private Ltd., India 
Orthophosphoric Acid ACI Labscan, RCI Labscan limited, 
Thailand. 
 
 
 
Table 21 (Continued) 
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Table 23: List of Apparatus Used  
Name Manufacturer Model 
Electronic Balance Shimadzu, Japan ATY-224 
High Pressure Liquid 
Chromatography (HPLC) 
Shimadzu, Japan SPD-M20A 
Prominence 
Friability Tester Electrolab, India EF-2 
Disintegration Tester Electrolab, India ED-2L 
Dissolution Tester Logan Instruments 
Corp., USA 
UDT-804 
Hardness Tester Electrolab, India EH-01 
pH meter Mettler Toledo, North 
America 
S220 
Disposable Syringe JMI Syringes & 
Medical Devices Ltd., 
Bangladesh 
5 mL 
Syringe Filter Restek, USA 25 mm, 
0.22 µm 
Filter Paper Whatman, UK 110 mm 
Membrane Filter Restek, USA 47 mm, 
0.22 µm 
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Appendix 2 
Sitagliptin 
Sitagliptin phosphate is an orally active Dipeptidyl peptidase 4 inhibitor which is a monohydrate 
phosphate salt. Its chemical name is 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-
5,6,7,8-tetrahydro-[3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate (1:1) 
monohydrate according to the IUPAC nomenclature and the chemical formula is C16H15F6N5O 
(European Medicines Agency, 2008). Figure 21 shows the chemical structure of sitagliptin. 
 
 
Figure 21: 2D Chemical Structure of Sitagliptin (Pubchem) 
Sitagliptin is a white to off-white crystalline, non-aqueous powder that exhibits pH dependent 
aqueous solubility. It is soluble in water and N,N-dimethyl formamide, slightly soluble in 
methanol, very slightly soluble in ethanol, acetone and acetonotrile and insoluble in isopropanol 
and isopropyl acetate. The above-mentioned active substance contains a chiral centre and is used 
as a single enantiomer (R) (European Medicines Agency, 2008; Sankar et al., 2013). 
It is stable if stored as directed condition and strong oxidizing agents must be avoided 
(Pubchem).  
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Toxicological Information (Pubchem) 
Sitagliptin may be risk factor in the development of pancreatitis. Human toxicity includes an 
increased risk of heart failure among patients with type 2 diabetes who already have pre-existing 
heart failure. Thermal decomposition of sitagliptin phosphate may produce toxic gases such as 
carbon monoxide, carbon dioxide, and nitrogen oxides. 
Metformin Hydrochloride 
Metformin is a hypoglycemic agent belonging to the biguanide class of antidiabetics. The 
chemical name of its hydrochloride form is 1, 1-Dimethylbiguanide monohydrochloride 
according to the IUPAC nomenclature. The chemical formula of metformin is C4H11N5and the 
chemical structure is given in Figure 22. 
 
Figure 22: 2D Chemical Structure of Metformin (Pubchem) 
It is a white to off-white crystalline, non-aqueous powder that is odourless and has a bitter taste. 
The compound is freely soluble in water, slightly soluble in ethanol and practically insoluble in 
chloroform, acetone, ether and in ethylene chloride. It has a specific crystalline form and has not 
demonstrated polymorphism or solvates. Particle size does not significantly influence dissolution 
of metformin hydrochloride, because it is freely soluble in water (European Medicines Agency, 
2008; Sankar et al., 2013). 
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Toxicological Information 
Lactic acidosis can occur because of the accumulation of metformin during treatment and the 
risk of metformin accumulation and lactic acidosis elevate with the degree of renal impairment 
(primary source).  On the other hand, metformin is seen to be bound to plasma proteins 
negligibly (Pubchem). 
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